Colospan

Company Overview

Snapshot

Founded in December 2010 by Boaz Assaf, Colospan operates with 11–50 employees. The company has raised $17M across 3 funding rounds from 6 investors. In June 2026, Colospan was acquired by Galmed Pharmaceuticals.

Business overview

Colospan is a clinical-stage medical device company focused on developing proprietary technology for colorectal surgery. The company's core product is a single-use, temporary intraluminal bypass device, the CG-100, designed to prevent anastomotic leaks and divert colonic stomas by reducing contact between fecal matter and the anastomotic site. Colospan serves the healthcare industry, specifically surgeons and hospitals, operating within the Health Tech & Life Sciences sector, with a focus on medical devices and medical treatment & therapeutics in gastroenterology and surgery.

Strategic signal

The acquisition of Colospan by Galmed Pharmaceuticals in June 2026 signals a strategic consolidation within the GI-focused medical device market. This move integrates Colospan's FDA Breakthrough Device-Designated technology and active U.S. pivotal IDE trial into a larger platform, indicating a strong validation of its technology and a clear path towards broader market access and commercialization. For investors, this suggests a successful exit for Colospan and a strengthened position for Galmed in a significant market segment.

Company Intelligence Q&A

What was the most recent significant corporate event for Colospan?

In June 2026, Colospan was acquired by Galmed Pharmaceuticals. This acquisition is intended to create a GI-focused platform, leveraging Colospan's FDA Breakthrough Device-Designated technology.

When did Colospan receive FDA approval for its Intraluminal Bypass Device?

Colospan announced FDA approval of its IDE for the Intraluminal Bypass Device in January 2020, positioning it as an alternative approach to diverting stoma.

Which hospital was the first in the U.S. to test Colospan's CG-100 device?

In December 2020, Henry Ford Hospital became the first in the U.S. to test Colospan's novel CG-100 Intraluminal Device in patients undergoing colorectal anastomosis.

Did Colospan receive any grants from European organizations?

In December 2021, Colospan received €8.2 million from the European Innovation Council for its novel colorectal surgery device.

Who were some of the investors in Colospan's September 2017 funding round?

In September 2017, Colospan received funding from investors including Anatomy Medical Technology Fund.